Celyad Oncology SA (EBR:CYAD)
Belgium
· Delayed Price · Currency is EUR 0.5480
+0.0040 (0.74%)
Mar 28, 2025, 5:25 PM CET
Celyad Oncology Cash Flow Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2014 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2014 - 2018 |
| Net Income | -7.75 | -8.45 | -40.94 | -26.51 | -17.2 | -28.63 | Upgrade
|
| Depreciation & Amortization | 0.56 | 0.72 | 1.37 | 1.44 | 1.83 | 1.79 | Upgrade
|
| Other Amortization | 0.07 | 0.07 | 0.07 | 0.08 | - | 0 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.01 | -1.06 | -5 | 0 | -0.03 | - | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | 35.08 | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | - | - | - | - | - | -0.18 | Upgrade
|
| Stock-Based Compensation | 0.5 | 0.94 | 1.62 | 2.17 | 2.78 | 2.78 | Upgrade
|
| Other Operating Activities | -0.13 | -0.93 | -16.21 | -5.23 | -12.18 | -3.34 | Upgrade
|
| Change in Accounts Receivable | -1.48 | -1.21 | 0.31 | - | - | -1.77 | Upgrade
|
| Change in Accounts Payable | -1.47 | -5.29 | -4.32 | - | - | 1.16 | Upgrade
|
| Change in Other Net Operating Assets | - | - | - | 1.41 | -2.87 | - | Upgrade
|
| Operating Cash Flow | -9.7 | -15.2 | -28.01 | -26.64 | -27.67 | -28.2 | Upgrade
|
| Capital Expenditures | -0.58 | -0.9 | -0.12 | -0.33 | -0.15 | -0.42 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.03 | 1.34 | - | - | 0.24 | - | Upgrade
|
| Divestitures | - | - | 6 | - | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -0.12 | -0.04 | - | -0.06 | -0.17 | -0.21 | Upgrade
|
| Investment in Securities | - | - | 1.09 | - | - | 9.38 | Upgrade
|
| Other Investing Activities | - | - | 0.24 | 0.27 | 0.24 | 0.23 | Upgrade
|
| Investing Cash Flow | -0.68 | 0.41 | 7.2 | -0.13 | 0.16 | 8.99 | Upgrade
|
| Long-Term Debt Repaid | - | -0.15 | -0.9 | -1.14 | -1.45 | -1.49 | Upgrade
|
| Net Debt Issued (Repaid) | -0.14 | -0.15 | -0.9 | -1.14 | -1.45 | -1.49 | Upgrade
|
| Issuance of Common Stock | 9.49 | 9.49 | - | 36.57 | - | 18.17 | Upgrade
|
| Other Financing Activities | 2.28 | 0.01 | 4.14 | 4.09 | 6.84 | 1.59 | Upgrade
|
| Financing Cash Flow | 11.63 | 9.36 | 3.24 | 39.52 | 5.4 | 18.28 | Upgrade
|
| Foreign Exchange Rate Adjustments | - | -0 | -0.01 | 0.03 | 0.01 | -0.26 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | -0 | - | - | - | - | -0 | Upgrade
|
| Net Cash Flow | 1.25 | -5.44 | -17.57 | 12.78 | -22.1 | -1.2 | Upgrade
|
| Free Cash Flow | -10.29 | -16.1 | -28.13 | -26.97 | -27.82 | -28.62 | Upgrade
|
| Free Cash Flow Margin | -14284.72% | -15785.29% | - | - | -556300.00% | -476983.33% | Upgrade
|
| Free Cash Flow Per Share | -0.29 | -0.63 | -1.25 | -1.73 | -2.00 | -2.29 | Upgrade
|
| Cash Interest Paid | 0.06 | 0.06 | 0.15 | - | - | - | Upgrade
|
| Levered Free Cash Flow | -7.88 | -14.45 | -13.83 | -13.48 | -11.11 | -14.57 | Upgrade
|
| Unlevered Free Cash Flow | -7.8 | -14.4 | -13.71 | -13.32 | -10.92 | -14.36 | Upgrade
|
| Change in Net Working Capital | 3.36 | 9.25 | 0.74 | -0.4 | -1.19 | -0.14 | Upgrade
|
Updated Sep 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.